Department of Physiology and Pathophysiology, Medical University, 1413 Sofia, Bulgaria.
Genetic Medico‑Diagnostic Laboratory Genica, 1612 Sofia, Bulgaria.
Mol Med Rep. 2022 Nov;26(5). doi: 10.3892/mmr.2022.12867. Epub 2022 Oct 5.
COVID‑19 patients with severe infection have been observed to have elevated auto‑antibodies (AAs) against angiotensin II receptor type 1 (AT1R) and endothelin (ET) 1 receptor type A (ETAR), compared with healthy controls and patients with favorable (mild) infection. AT1R and ETAR are G protein‑coupled receptors, located on vascular smooth muscle cells, fibroblasts, immune and endothelial cells, and are activated by angiotensin II (Ang II) and ET1 respectively. AAs that are specific for these receptors have a functional role similar to the natural ligands, but with a more prolonged vasoconstrictive effect. They also induce the production of fibroblast collagen, the release of reactive oxygen species and the secretion of proinflammatory cytokines (including IL‑6, IL‑8 and TNF‑α) by immune cells. Despite the presence of AAs in severe COVID‑19 infected patients, their contribution and implication in the severity of the disease is still not well understood and further studies are warranted. The present review described the major vascular homeostasis systems [ET and renin‑angiotensin‑aldosterone system (RAAS)], the vital regulative role of nitric oxide, the AAs, and finally the administration of angiotensin II receptor blockers (ARBs), so as to provide more insight into the interplay that exists among these components and their contribution to the severity, prognosis and possible treatment of COVID‑19.
与健康对照者和感染情况良好(轻症)的患者相比,严重感染的 COVID-19 患者被观察到存在针对血管紧张素 II 受体 1(AT1R)和内皮素 1 受体 A(ETAR)的自身抗体(AAs)升高。AT1R 和 ETAR 是位于血管平滑肌细胞、成纤维细胞、免疫细胞和内皮细胞上的 G 蛋白偶联受体,分别被血管紧张素 II(Ang II)和内皮素 1 激活。针对这些受体的特异性 AAs 具有与天然配体相似的功能作用,但具有更持久的血管收缩作用。它们还通过免疫细胞诱导成纤维胶原的产生、活性氧物质的释放和促炎细胞因子(包括 IL-6、IL-8 和 TNF-α)的分泌。尽管在严重 COVID-19 感染患者中存在 AAs,但它们在疾病严重程度中的作用和影响仍未得到很好的理解,需要进一步的研究。本文综述了主要的血管稳态系统(ET 和肾素-血管紧张素-醛固酮系统(RAAS))、一氧化氮、AAs 的重要调节作用,以及最后血管紧张素 II 受体阻滞剂(ARBs)的给药,以更深入了解这些成分之间的相互作用及其对 COVID-19 的严重程度、预后和可能治疗的贡献。